Institution Directory

Clinical trials at Memorial Sloan Kettering Cancer Center

Sites in New York, NY

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 9:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1683

Shown on this page

Current sort

Live official records

Conditions: Breast Cancer, Metastatic Triple-Negative Breast Cancer
Interventions: Eribulin, SDX-7320, Placebo; Drug · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 10
States / cities: Miami, Florida • Atlanta, Georgia • Basking Ridge, New Jersey + 7 more

Conditions: Gastrointestinal Stromal Tumor
Interventions: Sorafenib Tosylate; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2027
U.S. locations: 6
States / cities: Duarte, California • Sacramento, California • Chicago, Illinois + 3 more

Conditions: Hairy Cell Leukemia
Interventions: Vemurafenib, Obinutuzumab, Cladribine, Rituximab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 10
States / cities: Boston, Massachusetts • Rochester, Minnesota • Basking Ridge, New Jersey + 7 more

Conditions: Breast Cancer
Interventions: Cogmed Working Memory Training Program; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 69 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Interventions: durvalumab, carboplatin AUC 2/paclitaxel, External beam radiation (EBRT), esophagogastrectomy, Tremelimumab; Biological · Drug · Radiation + 1 more
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Montvale, New Jersey • Commack, New York + 4 more

Conditions: Adenocarcinoma, Pancreatic Ductal
Interventions: Autogene cevumeran, Atezolizumab, mFOLFIRINOX; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 30
States / cities: Los Angeles, California • Newport Beach, California • San Francisco, California + 22 more

Conditions: Brain Metastasases
Interventions: Stereotactic Radiosurgery, Surgical Resection; Radiation · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Glioblastoma, Gliosarcoma
Interventions: ERAS-801, ABBV-637, ABBV-155, Temozolomide, Radiotherapy; Drug · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 11
States / cities: Los Angeles, California • Miami, Florida • Indianapolis, Indiana + 8 more

Conditions: Metastatic Colon Cancer, Stage III Colon Cancer
Interventions: FOLFIRI Protocol, ACTIVE SURVEILLANCE, Nivolumab Protocol, Encorafenib/Binimetinib/Cetuximab Protocol, Trastuzumab + Pertuzumab; Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 3
States / cities: Boston, Massachusetts • New York, New York

Conditions: Advanced Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Lugano Classification Stage III Hodgkin Lymphoma AJCC v8, Lugano Classification Stage IV Hodgkin Lymphoma AJCC v8
Interventions: Biospecimen Collection, Computed Tomography, Dacarbazine, Doxorubicin, Echocardiography Test, Multigated Acquisition Scan, Nivolumab, Positron Emission Tomography, Vinblastine, Questionnaire; Procedure · Drug · Biological + 1 more
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 6
States / cities: Irvine, California • Palo Alto, California • Boston, Massachusetts + 3 more

Conditions: Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Recurrent Malignant Uterine Corpus Neoplasm, Stage IIIA Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage, Stage IIIB Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage, Stage IIIC Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage, Stage IVA Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage, Stage IVB Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage
Interventions: Bevacizumab, Carboplatin, Ixabepilone, Laboratory Biomarker Analysis, Paclitaxel, Temsirolimus; Biological · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 349 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2027
U.S. locations: 230
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 163 more

Conditions: Sarcoma, Desmoplastic Small Round Cell Tumor (DSRCT)
Interventions: irinotecan, temozolomide, and bevacizumab incorporated into an existing schedule of high dose alkylator; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 1 Year to 29 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2027
U.S. locations: 1
States / cities: New York, New York

About this Memorial Sloan Kettering Cancer Center institution page

What this page lists: ClinicalTrials.gov records that list Memorial Sloan Kettering Cancer Center in New York, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Memorial Sloan Kettering Cancer Center

Filter and sort this campus

Live official records

A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer

Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate

A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)

Rehabilitation of Cognitive Changes in Breast Cancer Survivors

Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer

A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC

A Study of Stereotactic Radiosurgery (SRS) in People With Brain Cancer Having Tumor Resection Surgery

Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma

Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer

Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor

About this Memorial Sloan Kettering Cancer Center institution page